SCHEMBL31014478

SCHEMBL31014478

O=C(O)c1ccc(F)c2c1cnn2C1CCCCO1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 3/20 0.44
▸ CYP4A11 Q02928 3/20 0.44
▸ RXRA P19793 1/20 0.41
▸ RXRB P28702 1/20 0.41
▸ RXRG P48443 1/20 0.41
▸ ATR Q13535 7/20 0.40
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ PRKAG1 P54619 4/20 0.36
▸ PRKAA1 Q13131 4/20 0.36
▸ PRKAB1 Q9Y478 4/20 0.36
▸ PRKAA2 P54646 3/20 0.36
▸ PRKAB2 O43741 2/20 0.36
▸ PRKAG3 Q9UGI9 2/20 0.36
▸ PRKAG2 Q9UGJ0 2/20 0.36
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MCL1 Q07820 1/20 0.33
▸ KDM4C Q9H3R0 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015503 0.87 CYP4F2 (0.42) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31179123 0.86 CYP4F2 (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL27227973 0.84 CYP4F2 (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31093887 0.83 CYP4F2 (0.39) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL24495524 0.81 LMNA (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20324247 0.81 CYP4F2 (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29686827 0.81 LMNA (0.45) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31179195 0.81 CYP4F2 (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL20324226 0.81 CYP4F2 (0.44) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL31093723 0.80 CYP4F2 (0.39) CYP4F2CYP4A11RXRARXRBRXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 — — US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 — — US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 CYP4F2 2249/4885CYP4A11 4503/4885RXRA 4128/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 CYP4F2 2249/4885CYP4A11 4503/4885RXRA 4128/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 CYP4F2 2249/4885CYP4A11 4503/4885RXRA 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback